Sugi Predict

Sugi Predict / Compounds / SCHEMBL759091

SCHEMBL759091

SCHEMBL759091

COc1ccc(-c2nc3ccccc3o2)cc1N

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.77
▸ PTGS2 P35354 1/20 0.58
▸ RAB9A P51151 4/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ ATM Q13315 1/20 0.57
▸ ALOX5 P09917 1/20 0.54
▸ ALDH1A1 P00352 7/20 0.53
▸ TP53 P04637 7/20 0.53
▸ KDM4E B2RXH2 6/20 0.53
▸ HPGD P15428 6/20 0.53
▸ MAPT P10636 4/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ LMNA P02545 2/20 0.53
▸ NFKB1 P19838 2/20 0.53
▸ STAT1 P42224 2/20 0.53
▸ NFKB2 Q00653 2/20 0.53
▸ RELA Q04206 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ GFER P55789 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28436509 0.87 NPC1 (1.00) NPC1PTGS2RAB9AMEN1KMT2A
SCHEMBL5834493 0.87 NPC1 (0.59) NPC1PTGS2RAB9AMEN1KMT2A
SCHEMBL5834171 0.86 NPC1 (0.58) NPC1PTGS2RAB9AALOX5ALDH1A1
SCHEMBL5835069 0.85 NPC1 (0.56) NPC1PTGS2RAB9AALOX5ALDH1A1
SCHEMBL5835051 0.84 NPC1 (0.56) NPC1PTGS2RAB9AALOX5ALDH1A1
Dimethylamine SCHEMBL5834922 0.84 NPC1 (0.55) NPC1PTGS2RAB9AMEN1KMT2A
SCHEMBL5834515 0.84 ALOX5 (0.70) NPC1PTGS2RAB9AALOX5ALDH1A1
SCHEMBL6681881 0.84 ALOX5 (0.59) NPC1PTGS2RAB9AMEN1KMT2A
SCHEMBL5835023 0.84 ALOX5 (0.62) NPC1PTGS2RAB9AMEN1KMT2A
SCHEMBL13171393 0.84 ALOX5 (0.78) NPC1PTGS2RAB9AALOX5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251694-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit (Oxford) Limited (GB) 2017-12-06 — — EP disclosed
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-16 — — US disclosed
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-09 — — US disclosed
US-8518980-B2 Treatment of Duchenne muscular dystrophy SUMMIT CORPORATION PLC (GB) 2013-08-27 — — US disclosed
US-8501713-B2 Drug combinations for the treatment of duchenne muscular dystrophy SUMMIT CORPORATION PLC (GB) 2013-08-06 — — US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 — — US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 — — US disclosed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 — — US disclosed
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT (OXFORD) LIMITED (GB) 2009-03-19 — — US disclosed
EP-1986633-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 — — EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
WO-2007091106-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 — — WO disclosed
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 — — US disclosed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 — — US disclosed
EP-1483261-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) 2004-12-08 — — EP disclosed
WO-2004067480-A2 SUBSTITUTED PHENYLUREA DERIVATIVES AS HDAC INHIBITORS OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-08-12 — — WO disclosed
WO-2004067480-A2 SUBSTITUTED PHENYLUREA DERIVATIVES AS HDAC INHIBITORS OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-08-12 — — WO disclosed
WO-2003074516-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 NPC1 2102/4885PTGS2 1244/4885RAB9A 1209/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 NPC1 58/4885PTGS2 1919/4885RAB9A 740/4885
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy PYGM, CPT1B, GYS1 NPC1 2477/4885PTGS2 2925/4885RAB9A 3748/4885
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY PYGM, CPT1B, GYS1 NPC1 2477/4885PTGS2 2925/4885RAB9A 3748/4885
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 NPC1 3637/4885PTGS2 4655/4885RAB9A 4325/4885
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 NPC1 3637/4885PTGS2 4655/4885RAB9A 4325/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 NPC1 58/4885PTGS2 1919/4885RAB9A 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.